HGH Fragment 176-191
HGH Fragment 176-191
The fat-burning fragment of HGH. Targets adipose tissue without growth-promoting effects. Ideal for pure fat loss protocols.
Save 10% when you pay in crypto (BTC · ETH · USDT)
Free shipping on orders over $250
Research use only. Products are not intended for human consumption.
We accept
Interac e-Transfer · BTC · ETH · USDT crypto −10%
How ordering works
- 01Place your order — no payment is taken on this site.
- 02Payment instructions arrive by email reply (Interac e-Transfer or crypto).
- 03Paid before 4 PM EST → same-day dispatch with tracking number.
Refrigerated SKU? Ships in an insulated cold-pack mailer. You receive a packaging photograph within 4 hours of dispatch.
- Janoshik verified — per-batch third-party purity testing
- Discreet — plain packaging, no brand markings
- Cold-pack mailer for refrigerated SKUs
- Refund + retest if a batch fails purity
Complete protocols
Build your stack
Stacks that include HGH Fragment 176-191 — protocol components priced together, bulk savings applied automatically.
At a glance
At a glance
- Concentration
- 5mg
- Purity
- 99.9%
- Route
- Subcutaneous injection (evening, pre-bed)
- Storage
- Lyophilized: 2–8°C, desiccated. Reconstituted: 2–8°C, ≤14 days (never freeze after reconstitution).
Compound profile
HGH Fragment 176-191 is a synthetic peptide corresponding to amino acids 176 through 191 of the human growth hormone molecule — the C-terminal region specifically responsible for GH's lipolytic activity. This 16-amino-acid fragment retains the fat-metabolizing properties of full-length somatropin while lacking the domains required for GH receptor activation, IGF-1 stimulation, and systemic growth signaling. The result is a compound that promotes adipose tissue breakdown without the anabolic, insulin-antagonistic, or proliferative effects associated with full-spectrum HGH administration.
HGH Fragment 176-191 is a synthetic peptide corresponding to amino acids 176 through 191 of the human growth hormone molecule — the C-terminal region specifically responsible for GH's lipolytic activity. This 16-amino-acid fragment retains the fat-metabolizing properties of full-length somatropin while lacking the domains required for GH receptor activation, IGF-1 stimulation, and systemic growth signaling. The result is a compound that promotes adipose tissue breakdown without the anabolic, insulin-antagonistic, or proliferative effects associated with full-spectrum HGH administration.
The fragment's mechanism of action is direct and targeted: it stimulates hormone-sensitive lipase (HSL) in adipocytes, accelerating the hydrolysis of stored triglycerides into free fatty acids and glycerol for oxidative metabolism. Crucially, it simultaneously inhibits lipogenesis — the enzymatic conversion of circulating glucose into new fat stores — creating a dual-action lipolytic environment. Research has demonstrated that Fragment 176-191 does not affect blood glucose levels, does not compete with insulin signaling, and does not stimulate long bone growth or organ hypertrophy. This selectivity makes it a fundamentally different research tool than full-length GH: it addresses the fat loss axis in isolation.
Researchers focused exclusively on fat reduction — without the broader systemic effects of full HGH — will find Fragment 176-191 the most targeted compound available for that purpose. It is commonly incorporated into cutting-phase research protocols alongside caloric deficit regimens, and pairs effectively with other lipolytic agents. It does not require the extended timelines of full GH protocols; measurable changes in fat oxidation markers have been observed within 4–6 weeks of consistent administration at standard research doses of 250–500mcg two to three times daily.
Reconstitution follows standard peptide protocol: add bacteriostatic water slowly against the vial wall, allow the lyophilized powder to dissolve without shaking, and refrigerate at 2–8°C. The reconstituted solution should be used within 21 days. Subcutaneous injection is the standard route, typically administered on an empty stomach (fasted state or at minimum 2–3 hours post-meal) to avoid insulin-mediated interference with the lipolytic mechanism. Many researchers dose upon waking and again mid-afternoon, timed around periods of low circulating insulin.
How to use
Injection technique, site rotation, and frequency guidance. Typical protocols split the weekly dose into 2 injections.
HGH Fragment 176-191 is supplied as a lyophilized (freeze-dried) powder and must be reconstituted with bacteriostatic water (BAC water) before use in a research setting.
- Clean the BAC water vial stopper and the peptide vial stopper with an alcohol swab. Allow to dry.
- Draw the required volume of BAC water into a sterile syringe (typically 1–3 mL depending on target concentration).
- Angle the needle so the water runs down the inside wall of the peptide vial. Avoid dispensing directly onto the powder.
- Do not shake. Gently swirl or roll until fully dissolved. Vigorous shaking can denature peptides.
- Refrigerate reconstituted solution at 2–8°C. Most reconstituted peptides are stable 14–30 days depending on compound.
Target concentration determines drawing volume. For dosing math, consult the dosing math guide.
Independent lab verification
Research disclaimer
For research and laboratory use only. Not for human or veterinary consumption. Nova Pharma sells to qualified researchers of legal age and ships to Canadian addresses only. See disclaimer and terms.
At a glance
At a glance
- Concentration
- 5mg
- Purity
- 99.9%
- Route
- Subcutaneous injection (evening, pre-bed)
- Storage
- Lyophilized: 2–8°C, desiccated. Reconstituted: 2–8°C, ≤14 days (never freeze after reconstitution).
Compound profile
HGH Fragment 176-191 is a synthetic peptide corresponding to amino acids 176 through 191 of the human growth hormone molecule — the C-terminal region specifically responsible for GH's lipolytic activity. This 16-amino-acid fragment retains the fat-metabolizing properties of full-length somatropin while lacking the domains required for GH receptor activation, IGF-1 stimulation, and systemic growth signaling. The result is a compound that promotes adipose tissue breakdown without the anabolic, insulin-antagonistic, or proliferative effects associated with full-spectrum HGH administration.
HGH Fragment 176-191 is a synthetic peptide corresponding to amino acids 176 through 191 of the human growth hormone molecule — the C-terminal region specifically responsible for GH's lipolytic activity. This 16-amino-acid fragment retains the fat-metabolizing properties of full-length somatropin while lacking the domains required for GH receptor activation, IGF-1 stimulation, and systemic growth signaling. The result is a compound that promotes adipose tissue breakdown without the anabolic, insulin-antagonistic, or proliferative effects associated with full-spectrum HGH administration.
The fragment's mechanism of action is direct and targeted: it stimulates hormone-sensitive lipase (HSL) in adipocytes, accelerating the hydrolysis of stored triglycerides into free fatty acids and glycerol for oxidative metabolism. Crucially, it simultaneously inhibits lipogenesis — the enzymatic conversion of circulating glucose into new fat stores — creating a dual-action lipolytic environment. Research has demonstrated that Fragment 176-191 does not affect blood glucose levels, does not compete with insulin signaling, and does not stimulate long bone growth or organ hypertrophy. This selectivity makes it a fundamentally different research tool than full-length GH: it addresses the fat loss axis in isolation.
Researchers focused exclusively on fat reduction — without the broader systemic effects of full HGH — will find Fragment 176-191 the most targeted compound available for that purpose. It is commonly incorporated into cutting-phase research protocols alongside caloric deficit regimens, and pairs effectively with other lipolytic agents. It does not require the extended timelines of full GH protocols; measurable changes in fat oxidation markers have been observed within 4–6 weeks of consistent administration at standard research doses of 250–500mcg two to three times daily.
Reconstitution follows standard peptide protocol: add bacteriostatic water slowly against the vial wall, allow the lyophilized powder to dissolve without shaking, and refrigerate at 2–8°C. The reconstituted solution should be used within 21 days. Subcutaneous injection is the standard route, typically administered on an empty stomach (fasted state or at minimum 2–3 hours post-meal) to avoid insulin-mediated interference with the lipolytic mechanism. Many researchers dose upon waking and again mid-afternoon, timed around periods of low circulating insulin.
How to use
Injection technique, site rotation, and frequency guidance. Typical protocols split the weekly dose into 2 injections.
HGH Fragment 176-191 is supplied as a lyophilized (freeze-dried) powder and must be reconstituted with bacteriostatic water (BAC water) before use in a research setting.
- Clean the BAC water vial stopper and the peptide vial stopper with an alcohol swab. Allow to dry.
- Draw the required volume of BAC water into a sterile syringe (typically 1–3 mL depending on target concentration).
- Angle the needle so the water runs down the inside wall of the peptide vial. Avoid dispensing directly onto the powder.
- Do not shake. Gently swirl or roll until fully dissolved. Vigorous shaking can denature peptides.
- Refrigerate reconstituted solution at 2–8°C. Most reconstituted peptides are stable 14–30 days depending on compound.
Target concentration determines drawing volume. For dosing math, consult the dosing math guide.
Independent lab verification
Research disclaimer
For research and laboratory use only. Not for human or veterinary consumption. Nova Pharma sells to qualified researchers of legal age and ships to Canadian addresses only. See disclaimer and terms.
Read the research
Reference articles from the lab covering this compound.
best of
Best Peptides for Fat Loss 2026: Complete Ranking (by Mechanism & Evidence)
Ranked guide to the best peptides for fat loss in 2026. Covers Semaglutide, Tirzepatide, Retatrutide, HGH Fragment, AOD-9604, CJC-1295, Ipamorelin, and MK-677 — with mechanisms, evidence levels, dosing, and cost per month.
comparisons
AOD-9604 vs Semaglutide vs HGH Fragment: Fat Loss Peptide Showdown
AOD-9604 vs semaglutide vs HGH Fragment 176-191 — mechanism comparison, effectiveness data, side effects, cost analysis, and selection guide for peptide-assisted fat loss in Canada.
compound guides
HGH Fragment 176-191: The Fat-Burning Peptide That Doesn't Touch Blood Sugar
HGH Fragment 176-191 isolates the fat-burning portion of growth hormone — 12.5x more potent at lipolysis than full HGH, with zero impact on blood sugar or insulin. Dosing, timing, AOD-9604 comparison, and Canadian sourcing.
